Johnson & Johnson (JNJ) is set to report earnings for the third-quarter of 2015 before the markets open tomorrow. Wall Street analysts are on average expecting JNJ to post $17.47 billion in sales during the quarter. This would show a 1.85% decrease from the Q215 revenue of $17.8 billion, and a decrease of 5.57% from the same period in Q314. EPS in Q315 are expected to come in at $1.45, a decline rate of 3.33% from $1.50 per share a year earlier. Meanwhile, EarningsWhisper.com reports a whisper number of $1.46 per share.
As a quick reminder, JNJ reported Q215 EPS of $1.71, $0.04 better than the Street’s consensus estimate. Revs decreased 8.72% year-over-year to $17.8 billion versus the $17.76 billion consensus.
On valuation measures, Johnson & Johnson shares are currently priced at 16.91x this year’s forecasted earnings. Ticker has a PEG and forward P/E ratio of 3.10 and 14.98, respectively. Price/Sales for the same period is 3.67 while EPS is 5.68. Currently there are 8 analysts that rate JNJ a ‘Buy’, 10 rate it a ‘Hold’. 1 analyst rates it a ‘Sell’. JNJ has a median Wall Street price target of $108.50 with a high target of $119.00.
In the past 52 weeks, shares of Sunnyvale, California-based company have traded between a low of $81.79 and a high of $109.49 and are now at $95.93.
Shares are down 3.89% year-over-year and 6.78% year-to-date.